Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zaleplon pharmacokinetics and absolute bioavailability.

A S Rosen1, P Fournié, M Darwish

  • 1Wyeth-Ayerst Research, Radnor, PA 19087, USA.

Biopharmaceutics & Drug Disposition
|April 22, 1999
PubMed
Summary

This study evaluated zaleplon

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a questionnaire on repeated eye-rubbing and ocular microtrauma in patients with keratoconus.

Journal francais d'ophtalmologie·2026
Same author

NGENUITY versus ARTEVO 800 in vitreoretinal surgery: A retrospective comparison of two different three-dimensional visualization systems in a French tertiary center.

Journal francais d'ophtalmologie·2025
Same author

Amniotic membrane grafting in the prevention of long-term retinal detachment secondary to giant full-thickness macular hole in Alport syndrome.

Journal francais d'ophtalmologie·2025
Same author

Long-Term Outcomes of Open Surgical Repair for Complex Aortoiliac Occlusive Disease in the Age of Endovascular Advancements.

Annals of vascular surgery·2025
Same author

[Bilateral diffuse uveal melanocytic proliferation (BDUMP) and ultra-widefield multimodal imaging].

Journal francais d'ophtalmologie·2025
Same author

[Six-month real-world outcomes of intravitreal clindamycin for ocular toxoplasmosis].

Journal francais d'ophtalmologie·2024

Area of Science:

  • Pharmacology and Therapeutics
  • Clinical Pharmacokinetics

Background:

  • Zaleplon is a novel nonbenzodiazepine hypnotic agent.
  • Understanding its pharmacokinetic profile is crucial for clinical use.
  • Presystemic metabolism significantly impacts oral drug bioavailability.

Purpose of the Study:

  • To determine the pharmacokinetics of zaleplon.
  • To assess the absolute oral bioavailability of zaleplon.
  • To evaluate the extent of presystemic metabolism of zaleplon.

Main Methods:

  • A partially randomized, single-dose, four-period crossover study.
  • 23 healthy subjects participated.
  • Administered intravenous (i.v.) and oral doses of zaleplon (1, 2.5, and 5 mg).

Main Results:

  • Zaleplon exhibited moderate to high systemic clearance (0.94 L/h/kg).
  • Rapid elimination with a half-life (t1/2) of approximately 1.05 hours.
  • Absolute oral bioavailability was determined to be 30.6%.

Conclusions:

  • Zaleplon undergoes significant presystemic metabolism.
  • The drug is rapidly absorbed orally, with elimination kinetics similar to i.v. administration.
  • The findings provide essential data for zaleplon's therapeutic application.

Related Experiment Videos